{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:45:07Z","timestamp":1757612707803,"version":"3.44.0"},"posted":{"date-parts":[[2025,8,20]]},"group-title":"In Review","reference-count":86,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,7,24]]},"abstract":"<title>Abstract<\/title>\n        <p>The first generation of Spike-based COVID-19 vaccines has reduced the risk of hospitalization, serious illness, and death caused by SARS-CoV-2 infections. However, waning immunity induced by these vaccines has failed to prevent immune escape, resulting in the emergence of multiple variants of concern (VOCs) and the prolongation of the COVID-19 pandemic. We hypothesize that a next-generation Coronavirus (CoV) vaccine incorporating highly conserved SARS-CoV-2 T cell antigens would confer potent, broad, and long-lasting cross-protective immunity against multiple VOCs. In the present study, we identified ten non-Spike antigens that are common and highly conserved among 8.7 million SARS-CoV-2 strains, twenty-one VOCs, SARS-CoV-1, MERS-CoV, seasonal human common cold CoVs, and animal CoVs. Seven of the ten antigens were preferentially recognized by CD8<sup>+<\/sup> and CD4<sup>+<\/sup> T cells from unvaccinated asymptomatic COVID-19 patients, irrespective of VOC infection. Three out of the seven conserved T cell antigens (NSP2, NSP14, and Nucleocapsid), when administered to golden Syrian hamsters: (<italic>i<\/italic>) Induced high frequencies of lung-resident polyfunctional antigen-specific CXCR5<sup>+<\/sup>CD4<sup>+<\/sup> T follicular helper (T<sub>FH<\/sub>) cells, GzmB<sup>+<\/sup>CD4<sup>+<\/sup> and GzmB<sup>+<\/sup>CD8<sup>+<\/sup> cytotoxic T cells (T<sub>CYT<\/sub>), and CD69<sup>+<\/sup>IFN-g<sup>+<\/sup>TNFa<sup>+<\/sup>CD4<sup>+<\/sup> and CD8<sup>+<\/sup> effector T cells (T<sub>EFF<\/sub>); (<italic>ii<\/italic>) Reduced morbidity, viral load, lung pathology, and COVID-19-like symptoms caused by various VOCs, including the highly pathogenic B.1.617.2 Delta variant and the recently circulating KP.3 Omicron variant; (<italic>iii<\/italic>) Improved protection conferred by spike-alone mRNA, and (iv) Conferred protection that last for more than one year post-vaccination. This multi-antigen CoV vaccine could be adapted for clinical use to confer potent, broad-spectrum, and durable cross-protective immunity against current and future variants of concern.<\/p>","DOI":"10.21203\/rs.3.rs-7208748\/v1","type":"posted-content","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T18:27:22Z","timestamp":1755714442000},"source":"Crossref","is-referenced-by-count":0,"title":["A Multi-Antigen Broad-Spectrum Coronavirus Vaccine Induces Potent and Durable Cross- Protection Against Infection and Disease Caused by Multiple SARS-CoV-2 Variants"],"prefix":"10.21203","author":[{"given":"Swayam","family":"Prakash","sequence":"first","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha R.","family":"Dhanushkodi","sequence":"additional","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afshana","family":"Quadiri","sequence":"additional","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hawa","family":"Vahed","sequence":"additional","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziz A.","family":"Chentoufi","sequence":"additional","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Gregoire","family":"Coulon","sequence":"additional","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabela Coimbra","family":"Ibraim","sequence":"additional","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assia El","family":"Babsiri","sequence":"additional","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delia F.","family":"Tifrea","sequence":"additional","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar J.","family":"Figueroa","sequence":"additional","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gil","sequence":"additional","affiliation":[{"name":"TechImmune, LLC, University Lab Partners"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey B.","family":"Ulmer","sequence":"additional","affiliation":[{"name":"TechImmune, LLC, University Lab Partners"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lbachir","family":"BenMohamed","sequence":"additional","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","first-page":"45","article-title":"Cross-Protection Induced by Highly Conserved Human B, CD4 (+,) and CD8 (+) T Cell Epitopes-Based Coronavirus Vaccine Against Severe Infection, Disease, and Death Caused by Multiple SARS-CoV-2 Variants of Concern","volume":"29","author":"Prakash S","year":"2024","unstructured":"Prakash, S. et al. Cross-Protection Induced by Highly Conserved Human B, CD4 (+,) and CD8 (+) T Cell Epitopes-Based Coronavirus Vaccine Against Severe Infection, Disease, and Death Caused by Multiple SARS-CoV-2 Variants of Concern. Frontiers In Immunology 29, 45\u201356 (2024).","journal-title":"Frontiers In Immunology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.2300392","article-title":"Anti-Viral and Anti-Inflammatory Therapeutic Effect of RAGE-Ig Protein Against Multiple SARS-CoV-2 Variants of Concern Demonstrated in K18-hACE2 Mouse and Syrian Golden Hamster Models","volume":"212","author":"Dhanushkodi NR","year":"2024","unstructured":"Dhanushkodi, N.R. et al. Anti-Viral and Anti-Inflammatory Therapeutic Effect of RAGE-Ig Protein Against Multiple SARS-CoV-2 Variants of Concern Demonstrated in K18-hACE2 Mouse and Syrian Golden Hamster Models. J Immunol 212, 1\u201310 (2024).","journal-title":"J Immunol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/jvi.01096-23","article-title":"A multi-epitope\/CXCL11 prime\/pull coronavirus mucosal vaccine boosts the frequency and the function of lung-resident memory CD4(+) and CD8(+) T cells and enhanced protection against COVID-19-like symptoms and death caused by SARS-CoV-2 infection","volume":"97","author":"Zayou L","year":"2023","unstructured":"Zayou, L. et al. A multi-epitope\/CXCL11 prime\/pull coronavirus mucosal vaccine boosts the frequency and the function of lung-resident memory CD4(+) and CD8(+) T cells and enhanced protection against COVID-19-like symptoms and death caused by SARS-CoV-2 infection. J Virol 97, 1\u201313 (2023).","journal-title":"J Virol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.4049\/jimmunol.2300315","article-title":"Challenges and Prospects in Developing Future SARS-CoV-2 Vaccines: Overcoming Original Antigenic Sin and Inducing Broadly Neutralizing Antibodies","volume":"211","author":"Evans JP","year":"2023","unstructured":"Evans, J.P. & Liu, S.L. Challenges and Prospects in Developing Future SARS-CoV-2 Vaccines: Overcoming Original Antigenic Sin and Inducing Broadly Neutralizing Antibodies. J Immunol 211, 1459\u20131467 (2023).","journal-title":"J Immunol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.4049\/jimmunol.2001438","article-title":"CD4(+), and CD8(+) T Cell Epitopes That Are Highly Conserved between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Targets for Preemptive Pan-Coronavirus Vaccines","volume":"206","author":"Prakash S","year":"2021","unstructured":"Prakash, S. et al. Genome-Wide B Cell, CD4(+), and CD8(+) T Cell Epitopes That Are Highly Conserved between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Targets for Preemptive Pan-Coronavirus Vaccines. J Immunol 206, 2566\u20132582 (2021).","journal-title":"J Immunol"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1172\/JCI137647","article-title":"SARS-CoV-2: A Storm is Raging","author":"Pedersen SF","year":"2020","unstructured":"Pedersen, S.F. & Ho, Y.C. SARS-CoV-2: A Storm is Raging. J Clin Invest (2020).","journal-title":"J Clin Invest"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1038\/s41467-022-34439-7","article-title":"Updated vaccine protects against SARS-CoV-2 variants, including Omicron (B.1.1.529) and prevents transmission in hamsters","volume":"13","author":"Sharma S","year":"2022","unstructured":"Sharma, S. et al. Updated vaccine protects against SARS-CoV-2 variants, including Omicron (B.1.1.529) and prevents transmission in hamsters. Nat Commun 13, 6644 (2022).","journal-title":"Nat Commun"},{"key":"ref8","first-page":"11","article-title":"SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines","author":"Sunagar R","year":"2023","unstructured":"Sunagar, R., Singh, A. & Kumar, S. SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. Vaccines (Basel) 11 (2023).","journal-title":"Vaccines (Basel)"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.cell.2021.03.052","article-title":"Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States","volume":"184","author":"Washington NL","year":"2021","unstructured":"Washington, N.L. et al. Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. Cell 184, 2587\u20132594 e2587 (2021).","journal-title":"Cell"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41564-021-00932-w","article-title":"SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse","volume":"6","author":"Konings F","year":"2021","unstructured":"Konings, F. et al. SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse. Nat Microbiol 6, 821\u2013823 (2021).","journal-title":"Nat Microbiol"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.3390\/v15081711","article-title":"Frequency of Atypical Mutations in the Spike Glycoprotein in SARS-CoV-2 Circulating from July 2020 to July 2022 in Central Italy: A Refined Analysis by Next Generation Sequencing","volume":"15","author":"Bellocchi MC","year":"2023","unstructured":"Bellocchi, M.C. et al. Frequency of Atypical Mutations in the Spike Glycoprotein in SARS-CoV-2 Circulating from July 2020 to July 2022 in Central Italy: A Refined Analysis by Next Generation Sequencing. Viruses 15 (2023).","journal-title":"Viruses"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1038\/s41467-025-58766-7","article-title":"Anti-nucleocapsid and anti-spike antibody trajectories in people with post-covid condition versus acute-only infections: a nested longitudinal case-control study within the Virus Watch prospective cohort","volume":"16","author":"Beale S","year":"2025","unstructured":"Beale, S. et al. Anti-nucleocapsid and anti-spike antibody trajectories in people with post-covid condition versus acute-only infections: a nested longitudinal case-control study within the Virus Watch prospective cohort. Nat Commun 16, 3686 (2025).","journal-title":"Nat Commun"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long COVID: major findings, mechanisms and recommendations","volume":"21","author":"Davis HE","year":"2023","unstructured":"Davis, H.E., McCorkell, L., Vogel, J.M. & Topol, E.J. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 21, 133\u2013146 (2023).","journal-title":"Nat Rev Microbiol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/s41591-024-03173-6","article-title":"Long COVID science, research and policy","volume":"30","author":"Al-Aly Z","year":"2024","unstructured":"Al-Aly, Z. et al. Long COVID science, research and policy. Nat Med 30, 2148\u20132164 (2024).","journal-title":"Nat Med"},{"year":"2025","author":"Hou Y","key":"ref15","unstructured":"Hou, Y. et al. Global Prevalence of Long COVID, its Subtypes and Risk factors: An Updated Systematic Review and Meta-Analysis. medRxiv (2025)."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1016\/j.cell.2021.09.010","article-title":"COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants","volume":"184","author":"Cevik M","year":"2021","unstructured":"Cevik, M., Grubaugh, N.D., Iwasaki, A. & Openshaw, P. COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants. Cell 184, 5077\u20135081 (2021).","journal-title":"Cell"},{"key":"ref17","article-title":"Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting","author":"Yisimayi A","year":"2023","unstructured":"Yisimayi, A. et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature (2023).","journal-title":"Nature"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1182556","DOI":"10.3389\/fimmu.2023.1182556","article-title":"Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern","volume":"14","author":"Renner TM","year":"2023","unstructured":"Renner, T.M. et al. Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern. Front Immunol 14, 1182556 (2023).","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1195299","DOI":"10.3389\/fimmu.2023.1195299","article-title":"SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern","volume":"14","author":"Ma Q","year":"2023","unstructured":"Ma, Q. et al. SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern. Front Immunol 14, 1195299 (2023).","journal-title":"Front Immunol"},{"key":"ref20","first-page":"e60","article-title":"Audio Interview: The FDA and Covid-19 Vaccines","volume":"387","author":"Rubin EJ","year":"2022","unstructured":"Rubin, E.J., Baden, L.R., Marks, P. & Morrissey, S. Audio Interview: The FDA and Covid-19 Vaccines. The New England journal of medicine 387, e60 (2022).","journal-title":"The New England journal of medicine"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(20)30743-1","article-title":"The COVID-19 pandemic in the USA: what might we expect?","volume":"395","author":"Chowell G","year":"2020","unstructured":"Chowell, G. & Mizumoto, K. The COVID-19 pandemic in the USA: what might we expect? Lancet 395, 1093\u20131094 (2020).","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0140-6736(23)00050-8","article-title":"The COVID-19 pandemic in 2023: far from over","volume":"401","author":"The L","year":"2023","unstructured":"The, L. The COVID-19 pandemic in 2023: far from over. Lancet 401, 79 (2023).","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1080\/14760584.2022.2110075","article-title":"Vaccines against SARS-CoV-2 variants and future pandemics","volume":"21","author":"Park T","year":"2022","unstructured":"Park, T. et al. Vaccines against SARS-CoV-2 variants and future pandemics. Expert Rev Vaccines 21, 1363\u20131376 (2022).","journal-title":"Expert Rev Vaccines"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition","volume":"22","author":"Nelde A","year":"2021","unstructured":"Nelde, A. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol 22, 74\u201385 (2021).","journal-title":"Nat Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng Y","year":"2020","unstructured":"Peng, Y. et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol 21, 1336\u20131345 (2020).","journal-title":"Nat Immunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e142167","DOI":"10.1172\/jci.insight.142167","article-title":"High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19","volume":"5","author":"Schub D","year":"2020","unstructured":"Schub, D. et al. High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19. JCI insight 5, e142167 (2020).","journal-title":"JCI insight"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette A","year":"2021","unstructured":"Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861\u2013880 (2021).","journal-title":"Cell"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity","volume":"183","author":"Rydyznski Moderbacher C","year":"2020","unstructured":"Rydyznski Moderbacher, C. et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell 183, 996\u20131012 e1019 (2020).","journal-title":"Cell"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"688436","DOI":"10.3389\/fimmu.2021.688436","article-title":"Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay","volume":"12","author":"Brand I","year":"2021","unstructured":"Brand, I. et al. Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay. Front Immunol 12, 688436 (2021).","journal-title":"Front Immunol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange EM","year":"2021","unstructured":"Bange, E.M. et al. CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med 27, 1280\u20131289 (2021).","journal-title":"Nat Med"},{"key":"ref31","article-title":"A T cell-based SARS-CoV-2 spike protein vaccine provides protection without antibodies","volume":"9","author":"Shi J","year":"2024","unstructured":"Shi, J. et al. A T cell-based SARS-CoV-2 spike protein vaccine provides protection without antibodies. JCI Insight 9 (2024).","journal-title":"JCI Insight"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.immuni.2016.05.006","article-title":"Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses","volume":"44","author":"Zhao J","year":"2016","unstructured":"Zhao, J. et al. Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity 44, 1379\u20131391 (2016).","journal-title":"Immunity"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41586-021-04186-8","article-title":"Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2","volume":"601","author":"Swadling L","year":"2022","unstructured":"Swadling, L. et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature 601, 110\u2013117 (2022).","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41590-022-01292-1","article-title":"Airway-resident T cells from unexposed individuals cross-recognize SARS-CoV-2","volume":"23","author":"Diniz MO","year":"2022","unstructured":"Diniz, M.O. et al. Airway-resident T cells from unexposed individuals cross-recognize SARS-CoV-2. Nat Immunol 23, 1324\u20131329 (2022).","journal-title":"Nat Immunol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41467-021-27674-x","article-title":"Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts","volume":"13","author":"Kundu R","year":"2022","unstructured":"Kundu, R. et al. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat Commun 13, 80 (2022).","journal-title":"Nat Commun"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1038\/s41467-023-42433-w","article-title":"Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination","volume":"14","author":"Mitsi E","year":"2023","unstructured":"Mitsi, E. et al. Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination. Nat Commun 14, 6815 (2023).","journal-title":"Nat Commun"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1038\/s41467-020-19770-1","article-title":"Architecture of a SARS-CoV-2 mini replication and transcription complex","volume":"11","author":"Yan L","year":"2020","unstructured":"Yan, L. et al. Architecture of a SARS-CoV-2 mini replication and transcription complex. Nat Commun 11, 5874 (2020).","journal-title":"Nat Commun"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-020-2739-1","article-title":"The coding capacity of SARS-CoV-2","volume":"589","author":"Finkel Y","year":"2021","unstructured":"Finkel, Y. et al. The coding capacity of SARS-CoV-2. Nature 589, 125\u2013130 (2021).","journal-title":"Nature"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.abd3871","article-title":"Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans","volume":"370","author":"Mateus J","year":"2020","unstructured":"Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 370, 89\u201394 (2020).","journal-title":"Science"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1188605","DOI":"10.3389\/fimmu.2023.1188605","article-title":"OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model","volume":"14","author":"Primard C","year":"2023","unstructured":"Primard, C. et al. OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model. Front Immunol 14, 1188605 (2023).","journal-title":"Front Immunol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1343716","DOI":"10.3389\/fimmu.2024.1343716","article-title":"High frequencies of alpha common cold coronavirus\/SARS-CoV-2 cross-reactive functional CD4(+) and CD8(+) memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients","volume":"15","author":"Coulon PG","year":"2024","unstructured":"Coulon, P.G. et al. High frequencies of alpha common cold coronavirus\/SARS-CoV-2 cross-reactive functional CD4(+) and CD8(+) memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients. Front Immunol 15, 1343716 (2024).","journal-title":"Front Immunol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-62703-260-5_2","article-title":"In vitro transcription of long RNA containing modified nucleosides","volume":"969","author":"Pardi N","year":"2013","unstructured":"Pardi, N., Muramatsu, H., Weissman, D. & Kariko, K. In vitro transcription of long RNA containing modified nucleosides. Methods Mol Biol 969, 29\u201342 (2013).","journal-title":"Methods Mol Biol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"e2201616119","DOI":"10.1073\/pnas.2201616119","article-title":"A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike","volume":"119","author":"Zhang Y","year":"2022","unstructured":"Zhang, Y. et al. A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike. Proc Natl Acad Sci U S A 119, e2201616119 (2022).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"e2110105119","DOI":"10.1073\/pnas.2110105119","article-title":"SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern","volume":"119","author":"Lu M","year":"2022","unstructured":"Lu, M. et al. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proc Natl Acad Sci U S A 119, e2110105119 (2022).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics","volume":"21","author":"Maier MA","year":"2013","unstructured":"Maier, M.A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther 21, 1570\u20131578 (2013).","journal-title":"Mol Ther"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","volume":"583","author":"Sia SF","year":"2020","unstructured":"Sia, S.F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834\u2013838 (2020).","journal-title":"Nature"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"Imai M","year":"2020","unstructured":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A 117, 16587\u201316595 (2020).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref48","doi-asserted-by":"crossref","DOI":"10.3390\/v13112251","article-title":"Development of a Hamster Natural Transmission Model of SARS-CoV-2 Infection","volume":"13","author":"Dowall S","year":"2021","unstructured":"Dowall, S. et al. Development of a Hamster Natural Transmission Model of SARS-CoV-2 Infection. Viruses 13 (2021).","journal-title":"Viruses"},{"key":"ref49","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001567","article-title":"Hamster and ferret experimental infection with intranasal low dose of a single strain of SARS-CoV-2","volume":"102","author":"Monchatre-Leroy E","year":"2021","unstructured":"Monchatre-Leroy, E. et al. Hamster and ferret experimental infection with intranasal low dose of a single strain of SARS-CoV-2. J Gen Virol 102 (2021).","journal-title":"J Gen Virol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41592-022-01447-w","article-title":"Animal models in SARS-CoV-2 research","volume":"19","author":"Chu H","year":"2022","unstructured":"Chu, H., Chan, J.F. & Yuen, K.Y. Animal models in SARS-CoV-2 research. Nat Methods 19, 392\u2013394 (2022).","journal-title":"Nat Methods"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"eabq1945","DOI":"10.1126\/scitranslmed.abq1945","article-title":"Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models","volume":"14","author":"Hajnik RL","year":"2022","unstructured":"Hajnik, R.L. et al. Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. Science translational medicine 14, eabq1945 (2022).","journal-title":"Science translational medicine"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"863554","DOI":"10.3389\/fimmu.2022.863554","article-title":"Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections","volume":"13","author":"Desmecht S","year":"2022","unstructured":"Desmecht, S. et al. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Front Immunol 13, 863554 (2022).","journal-title":"Front Immunol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/s41467-022-29413-2","article-title":"Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19","volume":"13","author":"Liu H","year":"2022","unstructured":"Liu, H. et al. Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat Commun 13, 1891 (2022).","journal-title":"Nat Commun"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/jmv.27526","article-title":"Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein","volume":"94","author":"Kumar S","year":"2022","unstructured":"Kumar, S., Thambiraja, T.S., Karuppanan, K. & Subramaniam, G. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J Med Virol 94, 1641\u20131649 (2022).","journal-title":"J Med Virol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: Current State of the Science","volume":"52","author":"Vabret N","year":"2020","unstructured":"Vabret, N. et al. Immunology of COVID-19: Current State of the Science. Immunity 52, 910\u2013941 (2020).","journal-title":"Immunity"},{"key":"ref56","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum Y","year":"2020","unstructured":"Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife 9 (2020).","journal-title":"Elife"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41591-021-01270-4","article-title":"Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera","volume":"27","author":"Xie X","year":"2021","unstructured":"Xie, X. et al. Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med 27, 620\u2013621 (2021).","journal-title":"Nat Med"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"e1009761","DOI":"10.1371\/journal.ppat.1009761","article-title":"SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence","volume":"17","author":"Boppana S","year":"2021","unstructured":"Boppana, S. et al. SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence. PLoS Pathog 17, e1009761 (2021).","journal-title":"PLoS Pathog"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.4049\/jimmunol.2101142","article-title":"Cutting Edge: Effect of Disease-Modifying Therapies on SARS-CoV-2 Vaccine-Induced Immune Responses in Multiple Sclerosis Patients","volume":"208","author":"Yuzefpolskiy Y","year":"2022","unstructured":"Yuzefpolskiy, Y. et al. Cutting Edge: Effect of Disease-Modifying Therapies on SARS-CoV-2 Vaccine-Induced Immune Responses in Multiple Sclerosis Patients. J Immunol 208, 1519\u20131524 (2022).","journal-title":"J Immunol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1038\/s41467-023-38020-8","article-title":"Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion","volume":"14","author":"Eser TM","year":"2023","unstructured":"Eser, T.M. et al. Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion. Nat Commun 14, 2952 (2023).","journal-title":"Nat Commun"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"9372","DOI":"10.1073\/pnas.1201130109","article-title":"RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10\/nsp14 exoribonuclease complex","volume":"109","author":"Bouvet M","year":"2012","unstructured":"Bouvet, M. et al. RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10\/nsp14 exoribonuclease complex. Proc Natl Acad Sci U S A 109, 9372\u20139377 (2012).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref62","article-title":"Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein","volume":"118","author":"Hsu JC","year":"2021","unstructured":"Hsu, J.C., Laurent-Rolle, M., Pawlak, J.B., Wilen, C.B. & Cresswell, P. Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein. Proc Natl Acad Sci U S A 118 (2021).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"E162-E171","DOI":"10.1073\/pnas.1718806115","article-title":"Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA","volume":"115","author":"Ferron F","year":"2018","unstructured":"Ferron, F. et al. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc Natl Acad Sci U S A 115, E162-E171 (2018).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref64","article-title":"Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection","volume":"218","author":"Bert N","year":"2021","unstructured":"Le Bert, N. et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J Exp Med 218 (2021).","journal-title":"J Exp Med"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1073\/pnas.0808790106","article-title":"Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase","volume":"106","author":"Chen Y","year":"2009","unstructured":"Chen, Y. et al. Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase. Proc Natl Acad Sci U S A 106, 3484\u20133489 (2009).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"e2117142119","DOI":"10.1073\/pnas.2117142119","article-title":"Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2","volume":"119","author":"Zhao Y","year":"2022","unstructured":"Zhao, Y. et al. Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2. Proc Natl Acad Sci U S A 119, e2117142119 (2022).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"e1000054","DOI":"10.1371\/journal.ppat.1000054","article-title":"SARS-coronavirus replication\/transcription complexes are membrane-protected and need a host factor for activity in vitro","volume":"4","author":"Hemert MJ","year":"2008","unstructured":"van Hemert, M.J. et al. SARS-coronavirus replication\/transcription complexes are membrane-protected and need a host factor for activity in vitro. PLoS Pathog 4, e1000054 (2008).","journal-title":"PLoS Pathog"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-1-4939-2438-7_22","article-title":"Studying the dynamics of coronavirus replicative structures","volume":"1282","author":"Hagemeijer MC","year":"2015","unstructured":"Hagemeijer, M.C. & de Haan, C.A. Studying the dynamics of coronavirus replicative structures. Methods Mol Biol 1282, 261\u2013269 (2015).","journal-title":"Methods Mol Biol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"e1011032","DOI":"10.1371\/journal.ppat.1011032","article-title":"Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T-cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2","volume":"19","author":"Becerra-Artiles A","year":"2023","unstructured":"Becerra-Artiles, A. et al. Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T-cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2. PLoS Pathog 19, e1011032 (2023).","journal-title":"PLoS Pathog"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"974364","DOI":"10.3389\/fimmu.2022.974364","article-title":"Recombinant COVID-19 vaccine based on recombinant RBD\/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity","volume":"13","author":"Ghaemi A","year":"2022","unstructured":"Ghaemi, A. et al. Recombinant COVID-19 vaccine based on recombinant RBD\/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity. Front Immunol 13, 974364 (2022).","journal-title":"Front Immunol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"e15821","DOI":"10.15252\/emmm.202215821","article-title":"A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells","volume":"14","author":"Appelberg S","year":"2022","unstructured":"Appelberg, S. et al. A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells. EMBO Mol Med 14, e15821 (2022).","journal-title":"EMBO Mol Med"},{"year":"2022","author":"Rice A","key":"ref72","unstructured":"Rice, A. et al. Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies. Front Immunol 13, 910136 (2022)."},{"key":"ref73","first-page":"177","article-title":"Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein","volume":"5","author":"Khan MS","year":"2022","unstructured":"Khan, M.S. et al. Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein. Antib Ther 5, 177\u2013191 (2022).","journal-title":"Antib Ther"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"105082","DOI":"10.1016\/j.micinf.2022.105082","article-title":"Heterologous chimpanzee adenovirus vector immunizations for SARS-CoV-2 spike and Nucleocapsid protect hamsters against COVID-19","volume":"25","author":"Hasanpourghadi M","year":"2023","unstructured":"Hasanpourghadi, M. et al. Heterologous chimpanzee adenovirus vector immunizations for SARS-CoV-2 spike and Nucleocapsid protect hamsters against COVID-19. Microbes Infect 25, 105082 (2023).","journal-title":"Microbes Infect"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"e252-e264","DOI":"10.1016\/S2666-5247(22)00027-1","article-title":"Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial","volume":"3","author":"Chiuppesi F","year":"2022","unstructured":"Chiuppesi, F. et al. Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. Lancet Microbe 3, e252-e264 (2022).","journal-title":"Lancet Microbe"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"1503954","DOI":"10.3389\/fimmu.2025.1503954","article-title":"Dynamics of spike-specific neutralizing antibodies across five-year emerging SARS-CoV-2 variants of concern reveal conserved epitopes that protect against severe COVID-19","volume":"16","author":"Zayou L","year":"2025","unstructured":"Zayou, L. et al. Dynamics of spike-specific neutralizing antibodies across five-year emerging SARS-CoV-2 variants of concern reveal conserved epitopes that protect against severe COVID-19. Front Immunol 16, 1503954 (2025).","journal-title":"Front Immunol"},{"year":"2024","author":"Prakash S","key":"ref77","unstructured":"Prakash, S. et al. A Broad-Spectrum Multi-Antigen mRNA\/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster Model. bioRxiv (2024)."},{"key":"ref78","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1038\/s41467-022-31005-z","article-title":"Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection","volume":"13","author":"Rappaport AR","year":"2022","unstructured":"Rappaport, A.R. et al. Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection. Nat Commun 13, 3289 (2022).","journal-title":"Nat Commun"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.cell.2023.04.007","article-title":"The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection","volume":"186","author":"Arieta CM","year":"2023","unstructured":"Arieta, C.M. et al. The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection. Cell 186, 2392\u20132409 e2321 (2023).","journal-title":"Cell"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41577-022-00809-x","article-title":"The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses","volume":"23","author":"Murray SM","year":"2023","unstructured":"Murray, S.M. et al. The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. Nat Rev Immunol 23, 304\u2013316 (2023).","journal-title":"Nat Rev Immunol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"106685","DOI":"10.1016\/j.isci.2023.106685","article-title":"COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient","volume":"26","author":"Morita R","year":"2023","unstructured":"Morita, R. et al. COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient. iScience 26, 106685 (2023).","journal-title":"iScience"},{"key":"ref82","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156978","article-title":"Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function","volume":"7","author":"Sabatino JJ","year":"2022","unstructured":"Sabatino, J.J., Jr. et al. Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function. JCI Insight 7 (2022).","journal-title":"JCI Insight"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","article-title":"Animal models for COVID-19","volume":"586","author":"Munoz-Fontela C","year":"2020","unstructured":"Munoz-Fontela, C. et al. Animal models for COVID-19. Nature 586, 509\u2013515 (2020).","journal-title":"Nature"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"1328905","DOI":"10.3389\/fimmu.2024.1328905","article-title":"Cross-protection induced by highly conserved human B, CD4(+), and CD8(+) T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern","volume":"15","author":"Prakash S","year":"2024","unstructured":"Prakash, S. et al. Cross-protection induced by highly conserved human B, CD4(+), and CD8(+) T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern. Front Immunol 15, 1328905 (2024).","journal-title":"Front Immunol"},{"key":"ref85","doi-asserted-by":"crossref","DOI":"10.1038\/s41596-024-01134-4","article-title":"mRNA lipid nanoparticle formulation, characterization and evaluation","author":"Ma Y","year":"2025","unstructured":"Ma, Y., VanKeulen-Miller, R. & Fenton, O.S. mRNA lipid nanoparticle formulation, characterization and evaluation. Nat Protoc (2025).","journal-title":"Nat Protoc"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1038\/s41467-020-17892-0","article-title":"A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation","volume":"11","author":"Muruato AE","year":"2020","unstructured":"Muruato, A.E. et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun 11, 4059 (2020).","journal-title":"Nat Commun"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7208748\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7208748\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T14:39:35Z","timestamp":1756996775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7208748\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":86,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-7208748\/v1","relation":{},"subject":[],"published":{"date-parts":[[2025,8,20]]},"subtype":"preprint"}}